Androgen Deprivation for Prostatic Carcinoma: A Rationale for Choosing Components
Open Access
- 2 July 1998
- journal article
- review article
- Published by Wiley in International Journal of Urology
- Vol. 5 (4) , 303-311
- https://doi.org/10.1111/j.1442-2042.1998.tb00356.x
Abstract
Ever since prostatic carcinoma was discovered to be dependent on the hormone androgen for its proliferation, androgen deprivation has been the treatment of choice for advanced cases of prostate cancer. Originally, treatment was limited to surgical castration or estrogen therapy. However, the introduction of luteinizing hormone‐releasing hormone analogues, antiandrogens, and newer treatment modalities, such as combined androgen blockade, has made choosing a treatment strategy more complex. Assuming that each modality is equally effective, emphasis should be placed on increasing patient tolerance and compliance by the use of long‐acting, nontoxic treatments with simple dosing regimens and minimal side effects. This review focuses on the factors influencing the final choice of treatment strategy.Keywords
This publication has 57 references indexed in Scilit:
- Maximal Androgen Blockade: Final Analysis of EORTC Phase III Trial 30853European Urology, 1998
- Absence of hepatic enzyme induction in prostate cancer patients receiving `Casodex' (bicalutamide)Anti-Cancer Drugs, 1996
- Practice Trends in the Diagnosis and Management of Prostate Cancer in the United StatesJournal of Urology, 1995
- GoserelinDrugs & Aging, 1995
- Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancerEuropean Journal Of Cancer, 1993
- NilutamideDrugs & Aging, 1993
- Hepatitis due to cyproterone acetateEuropean Journal Of Cancer, 1992
- FlutamideDrugs & Aging, 1991
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989